Disclosures: Vaclav Smid: Nothing to Disclose, Ksenyia Dryahina: Nothing to Disclose, Barbora Novkov: Nothing to Disclose, Stefan Swift: Nothing to Disclose, Simon Dostal: Nothing to Disclose, Sarka Svobodova: Nothing to Disclose, Martin Lenicek: Nothing to Disclose, Patrik Spanel: Nothing to Disclose, Radan Bruha: Nothing to Disclose 855 BASELINE CHARACTERISTICS IN WELL-COMPENSATED NASH CIRRHOSIS PATIENTS DIAGNOSED WITH OR WITHOUT A LIVER BIOPSY IN MAESTRO-NASH-OUTCOMES, A CLINICAL OUTCOME PHASE 3 STUDY ASSESSING THE EFFECT OF RESMETIROM IN WELL COMPENSATED NASH CIRRHOSIS Meena Bansal 1 Jrn Schattenberg 2 Kris Kowdley 3 Mazen Noureddin 4 Rohit Loomba 5 Rebecca Taub 6 Dominic Labriola 6 David Schneider 6 , 1 Icahn School of Medicine at Mount Sinai (ISMMS), 2 Saarland University Medical Center, Homburg and Saarland University, 3 Liver Institute Northwest, 4 Houston Methodist Hospital, 5 University of California, San Diego, 6 Madrigal Pharmaceuticals Background: MAESTRO- NASH Outcomes (NCT05500222) is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in well-compensated NASH cirrhosis
There is significant room to improve clinicians knowledge regarding the diagnosis and management of AAH
Improved insulin sensitivity is closely linked to favorable changes in body composition, such as decreased BMI and waist circumference, which are critical for PCOS patients who often present with obesity
Sweating or flushing: A warm, clammy feeling that can show up even when youre not doing anything physical
Each increase may temporarily reintroduce side effects
Your prescribing provider sends a detailed introductory video message with injection instructions, safety information, and lab orders
